大腸炎治療薬市場:パイプラインレビュー(2020年上半期)

◆英語タイトル:Colitis - Pipeline Review, H1 2020
◆商品コード:GDATA20MY0676
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2020年1月14日
◆ページ数:121
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Colitis – Pipeline Review, H1 2020
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Colitis – Pipeline Review, H1 2020, provides an overview of the Colitis (Gastrointestinal) pipeline landscape.

Colitis is swelling (inflammation) of the large intestine (colon). Colitis can have many different causes, including infections, including those caused by a virus, parasite, and food poisoning due to bacteria, inflammatory disorders (ulcerative colitis and Crohn’s disease), lack of blood flow (ischemic colitis), past radiation to the large bowel). Symptoms can include abdominal pain, bloating, bloody stools, chills, dehydration, diarrhea and fever. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Colitis – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I and Preclinical stages are 1, 2 and 26 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 7 molecules, respectively.

Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Colitis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Colitis (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Colitis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Colitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Introduction
Colitis – Overview
Colitis – Therapeutics Development
Colitis – Therapeutics Assessment
Colitis – Companies Involved in Therapeutics Development
Colitis – Drug Profiles
Colitis – Dormant Projects
Colitis – Discontinued Products
Colitis – Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Colitis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Colitis - Pipeline by AlfaSigma SpA, H1 2020
Colitis - Pipeline by Apollo Endosurgery Inc, H1 2020
Colitis - Pipeline by Citryll BV, H1 2020
Colitis - Pipeline by Concenter BioPharma Silkim Ltd, H1 2020
Colitis - Pipeline by enGene Inc, H1 2020
Colitis - Pipeline by ExCellThera Inc, H1 2020
Colitis - Pipeline by GeneFrontier Corp, H1 2020
Colitis - Pipeline by Genfit SA, H1 2020
Colitis - Pipeline by Himuka AM Pharma Corp, H1 2020
Colitis - Pipeline by Immodulon Therapeutics Ltd, H1 2020
Colitis - Pipeline by Immuron Ltd, H1 2020
Colitis - Pipeline by Inflazome Ltd, H1 2020
Colitis - Pipeline by Jubilant Biosys Ltd, H1 2020
Colitis - Pipeline by MAKScientific LLC, H1 2020
Colitis - Pipeline by Nippon Kayaku Co Ltd, H1 2020
Colitis - Pipeline by Principia Biopharma Inc, H1 2020
Colitis - Pipeline by Protagonist Therapeutics Inc, H1 2020
Colitis - Pipeline by RDD Pharma Ltd, H1 2020
Colitis - Pipeline by Riptide Bioscience Inc, H1 2020
Colitis - Pipeline by Scholar Rock Inc, H1 2020
Colitis - Pipeline by Serpinx BV, H1 2020
Colitis - Pipeline by Soligenix Inc, H1 2020
Colitis - Pipeline by Symbiotix Biotherapies Inc, H1 2020
Colitis - Pipeline by Synthetic Biologics Inc, H1 2020
Colitis - Pipeline by TaiRx Inc, H1 2020
Colitis - Pipeline by TPCera Ltd, H1 2020
Colitis - Pipeline by Vedanta Biosciences Inc, H1 2020
Colitis - Pipeline by Vitality Biopharma Inc, H1 2020
Colitis - Dormant Projects, H1 2020
Colitis - Dormant Projects, H1 2020 (Contd..1), H1 2020
Colitis - Dormant Projects, H1 2020 (Contd..2), H1 2020
Colitis - Discontinued Products, H1 2020

【掲載企業】

AlfaSigma SpA
Apollo Endosurgery Inc
Citryll BV
Concenter BioPharma Silkim Ltd
enGene Inc
ExCellThera Inc
GeneFrontier Corp
Genfit SA
Himuka AM Pharma Corp
Immodulon Therapeutics Ltd
Immuron Ltd
Inflazome Ltd
Jubilant Biosys Ltd
MAKScientific LLC
Nippon Kayaku Co Ltd
Principia Biopharma Inc
Protagonist Therapeutics Inc
RDD Pharma Ltd
Riptide Bioscience Inc
Scholar Rock Inc
Serpinx BV
Soligenix Inc
Symbiotix Biotherapies Inc
Synthetic Biologics Inc
TaiRx Inc
TPCera Ltd
Vedanta Biosciences Inc
Vitality Biopharma Inc

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[大腸炎治療薬市場:パイプラインレビュー(2020年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆